BioCentury
ARTICLE | Company News

Astellas acquires option to MD Anderson's AML mAb

April 4, 2015 12:09 AM UTC

The University of Texas MD Anderson Cancer Center has granted Astellas Pharma Inc. (Tokyo:4503) an option to license exclusive, worldwide rights to h8F4, an early stage antibody to treat acute myelogenous leukemia (AML).

The molecule is a humanized mAb targeting a peptide encoded within two different tumor antigens, proteinase 3 (PRTN3; PR3) and neutrophil elastase (NE; ELA2). ...